Amneal reports Q4 revenue $731M (+18% YoY), FY24 revenue $2.79B (+17%); guides FY25 $3.0-3.1B

Amneal Pharmaceuticals, Inc.

2024-FY EPS reported -$0.38 revenue$2,793,957,000

Q4 2024 GAAP net loss $31M ($0.10 diluted loss per share); adjusted net income $40M, adjusted EBITDA $155M.
Full year 2024 net revenue $2.79B (+17% YoY); GAAP net loss $117M; adjusted EBITDA $627M (+12% YoY).
All three segments (Affordable Medicines, AvKARE, Specialty) grew double-digits in FY24; CREXONT launched successfully.
FY25 guidance: net revenue $3.0-$3.1B, adjusted EBITDA $650-$675M; net leverage reduced to 3.9x a year ahead of target.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.